Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H14O6 |
Molecular Weight | 194.1825 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=DSCFFEYYQKSRSV-KLJZZCKASA-N
InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2-,3-,4-,5-,6+,7+/m0/s1
Methylinositol is a natural product in the family of inositols. It is found in many foods as well as pine tree bark. Methylinositol is found naturally in many foods and is commercially available as an approved food supplement. Methylinositol can mediate insulin action to improve glycemic control and insulin sensitivity in patients with type 2 diabetes mellitus, especially in patients with insulin resistance. It plays a positive role in regulating insulin-mediated glucose uptake in the liver through translocation and activation of the PI3K/Akt signaling pathway. The compound also modulates gamma-secretase to reduce A-betta production while sparing cleavage of the gamma-secretase substrate Notch. Methylinositol improves cognitive function and memory deficits in preclinical models of Alzheimer's disease (AD) neuropathology. Methylinositol was will tolerated in the population of AD subjects of varying age and severity. No serious adverse effects were detected in clinical trials. Many plant-derived compounds have excellent therapeutic potential against various human ailments. It was shown, that methylinositol mitigates tumor growth by modulating interleukins and hormones and induces apoptosis in rat breast carcinogenesis through inhibition of NF-κB.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094135 |
|||
Target ID: PI3K/Akt signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/26063468 |
|||
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20370563 |
|||
Target ID: GO:0038061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25827943 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://adisinsight.springer.com/drugs/800023662 DOI: 10.1016/j.jalz.2009.04.287 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
1500mg, 3000mg and 5000mg daily (during six weeks)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24641404
The exposure of D-pinitol at different concentrations such as 20, 40, 60, 80, 100 and 120 uM for 24hr resulted in decrease of MCF-7 cell proliferation in a dose dependent manner. It exhibits 47.3% reduced cell viability at 40 uM, and the viability was decreased more than 52% (cell proliferation) at 60 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
1908 (Number of products:3)
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
||
|
DSLD |
1367 (Number of products:28)
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TF9HZN9T0M
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
DTXSID50883108
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
PINITOL
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
10284-63-6
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
TF9HZN9T0M
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
28548
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
DB12969
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
C515760
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
1435864
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
m8831
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | Merck Index | ||
|
37208
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
1539814
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY | |||
|
128700
Created by
admin on Sat Dec 16 01:27:34 GMT 2023 , Edited by admin on Sat Dec 16 01:27:34 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD